Drug Trial Radar · NCT06922357
A Phase I/II of HRS-6719 in Patients With Advanced/Metastatic Solid Tumors
Last checked: Nov 20, 2026Latest source record: May 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
120
Planned (sponsor's estimate)
Start
Apr 24, 2025
Primary completion
Dec 2027
Study completion Dec 2027
Sponsor
- Lead sponsor
- Shandong Suncadia Medicine Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Apr 10, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase I/II, multicenter, open-label clinical trial with dose escalation/dose expansion/efficacy expansion phases, designed to evaluate the safety, tolerability, pharmacokinetic/pharmacodynamic (PK/PD) profiles, and antitumor efficacy characteristics of HRS-6719 in patients with MTAP-deficient advanced solid tumors.
Conditions
- Advanced/Metastatic Solid Tumors
Interventions
HRS-6719Drug
HRS-6719
Primary outcomes
What the sponsor says the trial is designed to measure.
- Dose Limited Toxicity (DLT)Time frame: 21 Days (first cycle)
- Maximum tolerable dose (MTD)Time frame: 21 Days (first cycle)
- Recommended dose for phase II (RP2D)Time frame: through phase I completion, an average of 1 years
- Incidence and severity of AETime frame: from Day1 to 30 days after last dose
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Barbin Medical University Cancer Hospital
Harbin, Heilongjiang, China · Recruiting
Zhejiang Cancer Hospital
Hangzhou, Zhejiang, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.